Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China flag China · Delayed Price · Currency is CNY
22.50
-0.32 (-1.40%)
Sep 11, 2026, 3:04 PM CST

SHE:300255 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-345.57-357.9-249.48-1,24017.51233.57
Depreciation & Amortization
69.1469.5573.774.756.9455.8
Other Amortization
2.082.211.050.80.62-
Loss (Gain) From Sale of Assets
0.250.230.7800.01-
Asset Writedown & Restructuring Costs
3.653.681.31.782.120.11
Loss (Gain) From Sale of Investments
-1.67-1.67-33.26-0.01--
Provision & Write-off of Bad Debts
33.4629.536.6115.386.51-0.13
Other Operating Activities
232.51218.66169.76730.5698.162.96
Change in Accounts Receivable
0.0612.29-21.01284.66-97.0691.52
Change in Inventory
6.944.36190161.28-156.01-398.02
Change in Accounts Payable
-99.6632.32-82.2513.8272.17-48.54
Operating Cash Flow
-96.9355.6856.2233.733.132.87
Operating Cash Flow Growth
--0.95%66.69%979.06%8.85%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-143.12-123.36-239.59-239.32-431.22-308.08
Sale of Property, Plant & Equipment
--0.060.020-
Investment in Securities
---0--
Other Investing Activities
0-05.770.45-0.10.78
Investing Cash Flow
-143.05-123.31-233.76-238.85-431.32-307.31

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-2,2012,0001,3462,8161,581
Total Debt Issued
2,8432,2012,0001,3462,8161,581
Long-Term Debt Repaid
--2,242-1,687-1,529-2,030-1,182
Lease Payments
-2.82-2.7-1.82-0.45--
Total Debt Repaid
-2,617-2,242-1,687-1,529-2,030-1,182
Net Debt Issued (Repaid)
225.74-41.31312.96-182.36786.08399.46
Common Dividends Paid
-128.12-118.69-119.93-107.73-124-61.89
Other Financing Activities
85.41101.46-11.3-4.85-8.635.39
Financing Cash Flow
183.03-58.54181.73-294.94653.44342.96

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-1.372.280.843.0312.96-3.49
Net Cash Flow
-58.32-123.895.03-497.03238.235.04

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-240.05-67.68-183.37-205.6-428.1-305.21
Free Cash Flow Growth
------
Free Cash Flow Margin
-27.93%-7.73%-17.79%-14.58%-18.32%-10.28%
Free Cash Flow Per Share
-0.28-0.07-0.20-0.22-0.49-0.33
Levered Free Cash Flow
-177.3682.38-43.8855.71-500.03-469.98
Unlevered Free Cash Flow
-119.01142.9520.39115.97-441.88-431.04
Free Cash Flow After Leases
-242.87-70.38-185.2-206.05-428.1-305.21

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
23.2628.9822.83149.8370.81163.73
Change in Working Capital
-90.7791.3985.78450.73-178.69-349.44